1. Home
  2. GKOS vs HSIC Comparison

GKOS vs HSIC Comparison

Compare GKOS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$180.54

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Logo Henry Schein Inc.

HSIC

Henry Schein Inc.

HOLD

Current Price

$84.83

Market Cap

9.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
HSIC
Founded
1998
1932
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
9.5B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
GKOS
HSIC
Price
$180.54
$84.83
Analyst Decision
Strong Buy
Buy
Analyst Count
13
16
Target Price
★ $199.31
$96.87
AVG Volume (30 Days)
979.8K
★ 1.2M
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.21
EPS
N/A
★ 1.74
Revenue
$507,442,000.00
★ $13,201,995,000.00
Revenue This Year
$36.30
$5.17
Revenue Next Year
$23.25
$4.00
P/E Ratio
★ N/A
$48.84
Revenue Growth
★ 32.33
5.94
52 Week Low
$80.91
$62.44
52 Week High
$191.62
$92.18

Technical Indicators

Market Signals
Indicator
GKOS
HSIC
Relative Strength Index (RSI) 65.62 49.21
Support Level $175.04 $83.23
Resistance Level $184.68 $88.18
Average True Range (ATR) 6.45 1.67
MACD 1.90 0.10
Stochastic Oscillator 80.18 34.91

Price Performance

Historical Comparison
GKOS
HSIC

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.

Share on Social Networks: